XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.1
11. Stock-based Compensation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
May 31, 2020
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
May 15, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share-Based Payment Arrangement, Noncash Expense     $ 2,232,000 $ 705,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period     6,250      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period     0      
Share-Based Payment Arrangement, Option [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Description of share-based compensation arrangement by share-based payment award     The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of common stock set by the Company’s board of directors on or prior to each such January 1. On January 1, 2022, in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under the 2012 Plan. As of March 31, 2022, an aggregate of      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized 4,713,637,000,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized     15,817,818      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant     5,500,000      
Options granted in period     3,000,000      
Weighted-average exercise price per share granted in period     $ 1.47      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period     6,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value     $ 100,000 $ 0    
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount     $ 10,200,000      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years 7 months 6 days      
Employee Stock Purchase Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Description of share-based compensation arrangement by share-based payment award   On May 15, 2020, the Company’s stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"), whereby qualified employees are allowed to purchase limited amounts of the Company’s common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company’s Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company on or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP. During the three months ended March 31, 2022, the Company sold 84,078 shares of common stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were approximately $17,000 for the three months ended March 31, 2022.        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized 1,055,004,000,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized           1,000,000.0
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent   0.85%        
Stock Issued During Period, Shares, Employee Stock Purchase Plans     84,078      
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent     0.15%      
Share-Based Payment Arrangement, Noncash Expense     $ 17,000      
Inducement Planof 2019 [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Description of share-based compensation arrangement by share-based payment award     On July 28, 2019, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized     1,000,000      
Incentive Stock Option [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Options granted in period     560,605      
Weighted-average exercise price per share granted in period     $ 1.46      
Term of option grant     10 years      
Vesting percentage on the first anniversary     25.00%      
Non Qualified Stock Options To Employees [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Options granted in period     2,299,395      
Non Qualified Stock Options To Non Employee Directors [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Options granted in period     140,000      
Weighted-average exercise price per share granted in period     $ 1.56      
Term of option grant     10 years      
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period     12 months      
Performance Shares [Member] | P S Uto Executives [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share-Based Payment Arrangement, Noncash Expense     $ 1,300,000   $ 4,900,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award         During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the three months ended March 31, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and no compensation cost related to these milestones was recognized.  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period         2,400,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value         $ 4.31  
Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount     $ 0